FDA’s FY 2013 Drug GMP Warning Letters
This article was originally published in The Gold Sheet
Executive Summary
Topicals and injectables were the most common types of products to receive drug GMP warning letters in FY 2013. All 43 warning letters are listed here by dosage form with the key issues described.
You may also be interested in...
EMA Reviewing Bavarian Nordic’s Imvanex For Vaccination Against Monkeypox
EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.
EMA, HTA Bodies & Payers Explore Common Ground On Use Of RWE
A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers.
Biosimilars Forum Welcomes PBM Transparency Act
Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.